PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'The Center for Biomedical Research, NHC Key Laboratory of Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, 1095 Jiefang Ave., Wuhan 430030, China.\', \'Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guilin Medical University, 212 Renmin Road, Guilin 541000, China.\', \'The Center for Biomedical Research, NHC Key Laboratory of Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, 1095 Jiefang Ave., Wuhan 430030, China. wangcy@tjh.tjmu.edu.cn xiongdoctor@qq.com huilanz_76@163.com.\', \'Department of Respiratory Medicine, Shanghai Ninth People\'s Hospital, Shanghai Jiaotong University School of Medicine, 639 Zhizaoju Lu, Shanghai 200011, China.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • eabb607510.1126/sciadv.abb6075
?:hasPublicationType
?:journal
  • Science advances
is ?:pmid of
?:pmid
?:pmid
  • 33277324
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 5.817
?:rankingScore_hIndex
  • 46
is ?:relation_isRelatedTo_publication of
?:title
  • MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all